View Article Online View Journal

Organic & Biomolecular Chemistry

Accepted Manuscript

This article can be cited before page numbers have been issued, to do this please use: C. SAPPINO, A. Mari, A. Mantineo, M. Moliterno, M. Palagri, C. Tatangelo, L. Suber, P. Bovicelli, A. Ricelli and G. Righi, *Org. Biomol. Chem.*, 2018, DOI: 10.1039/C8OB00165K.



This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.

You can find more information about Accepted Manuscripts in the **author guidelines**.

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard <u>Terms & Conditions</u> and the ethical guidelines, outlined in our <u>author and reviewer resource centre</u>, still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains.



rsc.li/obc

ARTICLE

Received 00th January 20xx,

Accepted 00th January 20xx

DOI: 10.1039/x0xx00000x

www.rsc.org/



New chiral amino alcohol ligands for catalytic enantioselective addition of diethylzinc to aldehydes

Carla Sappino, ^{a†} Alessandra Mari, ^{a†} Agnese Mantineo, ^a Mauro Moliterno, ^a Matteo Palagri, ^a Chiara Tatangelo, ^a Lorenza Suber, ^b Paolo Bovicelli, ^c Alessandra Ricelli, ^c and Giuliana Righi^{c†*}

E-mail: giuliana.righi@cnr.it

Abstract. A study aimed at the synthesis and structure optimization of new, efficient, optically active β -amino alcohol ligands with a structure suitable for immobilization on magnetite nanoparticles has been carried out. The optimized homogeneous amino alcohol catalysts **13a** and **13b**, the chirality of which arises from the Sharpless epoxidation of suitable allyl alcohols, were tested by employing the well-established enantioselective amino alcohol-promoted addition of diethylzinc to benzaldehyde giving the corresponding benzyl alcohol with nearly quantitative yield and ee=95%. Then their broad applicability as chiral catalysts was evaluated by carrying out the same reaction on a family of aldehydes, including variously substituted aromatic ones as well as an aliphatic analogue. The results have confirmed the validity of the fine-tuning process performed on ligands **13a** and **13b**. In fact, both exhibited excellent catalytic activity as demonstrated by the chemical yields and *ee* obtained from all the tested aldehydes, almost independent of the position and type of substitution in the aromatic ring.

Introduction

Published on 14 February 2018. Downloaded by Kocaeli Universitesi on 15/02/2018 14:16:49.

In recent decades, research on asymmetric catalysis has grown considerably, culminating in award of the 2001 Nobel Prize in Chemistry to Knowles,¹ Noyori² and Sharpless³ "for their work on chirally catalyzed hydrogenation and oxidation reactions". Most of the chiral catalysts developed so far are small, optically active organic molecules able to form complexes with transition metals trough heteroatoms incorporated in their structure (commonly P, O, N, S). Research on new efficient catalysts relies mostly on trial-and-error, thereby having a consistent number of structurally correlated molecules, available for testing in the selected enantioselective reaction becomes a decisive factor. For this reason, it is important to design a structure which includes an easily tunable site, in order to access to many potential catalysts with relatively modest effort.

 β -amino alcohols represent one of the most studied classes of chiral ligands/auxiliaries. They have been used, both in acyclicand cyclic-derivative form, since the beginning of asymmetric synthesis.⁴ Enantioselective addition of organometallic reagents to aldehydes affords optically active secondary alcohols, and, at the same time, leads to the formation of a new C-C bond. After the work of Noyori,⁵ 1,2-amino alcohols have become the preferred choice in the enantioselective addition of dialkylzincs to aldehydes. This reaction has become a classical test in the design of new amino alcohol chiral ligands, and many new catalysts have been developed. To mention some N,N-dialkyInorephedrines⁶ examples. and substituted aminophenylalcohols^{7,8} led to outstanding results. Due to our research on stereocontrolled synthesis of amino alcohols,^{9,10} we were involved in the development of a novel class of amino alcohol ligands. Moreover, we focused on the design and synthesis of ligands that display a functionality suitable for their covalent anchoring to magnetite nanoparticles (Figure 1).^{11, 12} The use of magnetic nanoparticles has recently led to the development of new catalysts that combine the advantages of both homogeneous and heterogeneous catalysis, leading to easily recyclable highly efficient systems, and thereby reducing the process's economic and environmental effects.¹³

Herein we report the design and synthesis of a novel, versatile and easily tunable class of amino alcohol ligands, developed through the well-established enantioselective addition of diethylzinc to aldehydes. Moreover, it is a specific feature of these new ligands that their stucture is enriched with a functionality for a future immobilization on magnetically recoverable nanoparticles.

^{a.} Dip. Chimica, Sapienza Università di Roma, p.le A. Moro 5, 00185 Roma, Italy

^{b.} CNR-Istituto di Struttura della Materia-Via Salaria km 29,300-00015

Monterotondo Scalo (Roma) Italy.

^c CNR-IBPM- c/o Dip. Chimica, Sapienza Università di Roma, p.le A. Moro 5, 00185 Roma, Italy

⁺ These authors contributed equally to this work.

Electronic Supplementary Information (ESI) available: [details of any supplementary information available should be included here]. See DOI: 10.1039/x0xx00000x

ARTICLE

Results and Discussion

Unfunctionalized amino alcohol ligands

First, to understand the influence of regio- and stereochemistry of the amino alcohol moiety on the catalytic activity, amino alcohol ligands **1**, **2**, **3** were prepared (Figure 1).

All the ligands were obtained starting from the optical active epoxy alcohol **5a** carrying out the Sharpless AE on the allylic alcohol **4a**. The epoxy alcohol **5a** was transformed into the corresponding carboxylic acid, and then coupled with allylamine to afford the amide **6a** (Scheme 1).[§] The aminolysis of amide **6a** (Scheme 1) afforded the anti stereochemistry of the amino alcohol moiety in the mixture of regioisomers **1** and **2** (ratio 50:50). In contrast, obtaining the *syn* stereochemistry in the amino alcohol system required a two-step process: an initial oxirane ring opening by means of MgBr₂ in diethyl ether at room temperature followed by a nucleophilic substitution by azide (Scheme 2). Finally, the azido alcohol **8** was subjected to reduction employing PPh₃, thereby resulting in the corresponding amino alcohol ligand **3** (Scheme 2).

At this point, these optically active amino alcohols were tested in the addition of diethylzinc to benzaldehyde, employing a 6% molar amount of ligand and performing the reactions at room temperature in toluene. Unfortunately, these ligands had no significant catalytic activity: in all cases, reaction yields were comparable to those obtained in the absence of a ligand (24-44%) and no asymmetric induction was observed.



Figure 1: Structure of amino alcohol ligands 1, 2 and 3



Scheme 1: a) TBHP, Ti(O-iPr)₄, L-(+)-DET, CH₂Cl₂ dry, -20 °C, 12h, 88% b) NalO₄, RuCl₃, CH₃CN/CCl₄/buffer pH 7, r.t., 12h c) allylamine, EDC/HOAt, CH₂Cl₂, r.t., 2h, 53-75% d) NH₃/H₂O, 65 °C, 12 h, 72%



Scheme 2: a) MgBr₂, Et₂O, r.t., 8h, 73% b) NaN₃, 18-crown-6, DMSO, 60 °C, 12h, 88% c) PPh₃, MeOH/H₂O, r.t., 8h, 68%

N,N-dialkylated amino alcohol ligand

In light of the disappointing results obtained and considering the numerous examples of N,N-dialkylated amino alcohol ligands present in the literature, we decided to functionalize the nitrogen of **1**, **2** and **3**, which afforded the corresponding dipropyl derivatives in moderate yields (Scheme 3).

Amino alcohols **9-11** were then evaluated as ligands in the reaction test. As shown in Table 1, yields increased significantly and enantiomeric excesses, albeit modest, were observed. In particular, these preliminary results seem to indicate that the amino alcohol regiochemistry has no influence on catalytic efficiency (entries 1,2), whereas the *syn* stereochemistry (entry 3) is less efficient than that of the *anti* one (entries 1,2), in agreement with some results already reported.¹⁴



Scheme 3: a) n-PrI, K2CO3, CH3CN, reflux, 12h, 55-70%

Table 1: Addition of Et_2Zn to benzaldehyde catalyzed byligands 9, 10 and 11

СНО	Et ₂ Zn, toluene , rt ligand 9-11 (6 mol%)		
Entry	ligand	yield (%) ^b	ee (%)
1	9	89	28
2	10	86	27
3	11	76	0

^{a)} All the experiments were performed under identical conditions (6h).
 ^{b)} Chemical yields are referred to isolated compounds

Screening on the effect of the R and R' groups

The catalytic effect showed by ligands **9** and **10** prompted us to synthetize a set of N,N-dialkylated amino alcohols with different R and R' groups following a previously reported methodology (Scheme 4).¹⁵

The amino alcohols **12a-g** were evaluated as chiral ligands in the reaction test. As shown in Table 2, no significant effects of the R and R' groups were observed: yields were generally very good, even if the level of asymmetric induction remained very moderate. Lower catalytic activity was registered when R=phenyl, although the structure of **12f** and **12g** is very similar to that of efficient enantioselective ligands reported in literature.⁷ The collected data have led us to hypothesize that a carbonyl group adjacent to the amino alcohol site has an unfavourable effect on the formation of the chiral complex responsible for the enantiofacial differentiation.¹⁶⁻¹⁷



 Table 2: Addition of Et₂Zn to benzaldehyde catalyzed by ligands 12a-g

СНО	Et ₂ Zn, tol ligand (6 m	uene , rt 12a-g ol%)	OH *
entry	ligand	yield (%) ^b	ee (%)
1	12a	87	25
2	12b	88	29
3	12c	93	31
4	12d	78	16
5	12e	80	15
6	12f	61	7
7	12g	50	4

a) All the experiments were performed under identical conditions
 (6h). ^{b)} Chemical yields are referred to isolated compounds

Optimization of ligand structure

To verify our hypothesis, we introduced a spacer between the carbonyl group and the amino alcohol moiety; in particular, we considered use of a double bond, expected to regioselectively direct the nucleophilic ring opening of the epoxide, to be appropriate. The α , β -unsaturated amides **13a-f** and **14** were synthesized in satisfactory yields from the corresponding optically active epoxy alcohol by means of the sequence described in Scheme 5. It is noteworthy that the final aminolysis of the epoxy ring, expected to be effortless due to the high reactivity of the allylic position, required testing of different reaction conditions to enable achievement of the desired amino alcohol in good yields.§§ In particular, by employing LiClO4 in refluxing acetonitrile, the α , β -unsaturated epoxy amide was completely converted into the corresponding amino alcohol derivatives 13a-e. Whereas R=propyl and cyclohexyl substrates led to a single regioisomer, the reaction on substrate with R=phenyl produced both amino alcohols 13f and 14. §§§

Finally, the new set of amino alcohols 13a-f and 14 was tested in the usual addition of diethylzinc to benzaldehyde. As reported in Table 3, the results with R=cyclohexyl were

ARTICLE

ARTICLE

excellent, especially for R'=morpholine and dibutylamine (entries 1 and 2).



View Article Online DOI: 10.1039/C8OB00165K

Page 4 of 11



Scheme 5: a) TEMPO/IBDA, CH₂Cl₂, r.t., 4h, 72-81% b) diethylphosphonoacetic acid, BuLi, THF, -70°C., 8h c) allylamine, EDC, HOAt, CH₂Cl₂, r.t., 8h, 65-72% from **15** d) LiClO₄, R'₂NH, CH₃CN, reflux, 12h, 72-84%

Table 3:	Addition of Et ₂ Zn	o benzaldehyde	catalyzed by	ligands 13a-f and 14
----------	--------------------------------	----------------	--------------	----------------------

Entry	ligand	yield (%) ^b	ee (%)
1	13 a	>95	90
2	13b	>95	95
3	13c	84	83
4	13d	53	10
5	13e	39	54
6	13f	70	52
7	14	71	38

^{a)} All the experiments were performed under identical conditions (6h).

^{b)} Chemical yields are referred to isolated compounds

Scope

At this point, with the optimized ligands **13a** and **13b** in hand, we decided to employ them in the addition of diethylzinc to a family of aldehydes, including variously substituted aromatic ones as well as an aliphatic analogue. Results shown in Table 4 have confirmed the consistency of the fine-tuning process performed on ligands. Both **13a** and **13b** exhibited excellent

catalytic activity as demonstrated by the chemical yields and *ee* obtained from all the tested aldehydes, almost independent of the position and type of substitution in the aromatic ring. Generally, **13b** seems to be a slightly more efficient ligand than **13a**, the difference being particularly noticeable with 4-MeO-benzaldehyde (entry 7). It is noteworthy that the catalytic efficiency and asymmetric induction remain remarkable also when the tested aldehyde was aliphatic (entry 4).

ARTICLE

Table 4: Addition of Et₂Zn to different aldehydes catalyzed by ligands 13a and 13b

b View Article Online DOI: 10.1039/C8OB00165K

R- C HO	Et₂Zn toluene or hexane, rt	но н
	ligand 13 a,b (6 mol%)	R

entry	Aldehyde	Yield (%) ^b 13a	Yield (%) ^b 13b	<i>ee</i> (%) 13a	<i>ee</i> (%) 13b	Product
1	Benzaldehyde	>95	>95	90	95	18a
2	1-Naphthaldehyde	>95	>95	83	97	18b
3	Cinnamaldehyde	88	88	88	87	18c
4	3-Thiophenecarboxaldehyde	>95	>95	92	95	18d
5	Cyclohexanecarboxaldehyde	90	88	88	80	18e
6	2-Methoxybenzaldehyde	>95	>95	96	96	18f
7	3-Methoxybenzaldehyde	60	60	92	97	18g
8	4-Methoxybenzaldehyde	65	99	58	97	18h
9	2-Methylbenzaldehyde	95	94	95	98	18 i
10	3-Methylbenzaldehyde	>95	>95	93	98	18j
11	4-Methylbenzaldehyde	>95	>95	92	97	18k
12	2-Fluorobenzaldehyde	88	88	90	90	181
13	2-Chlorobenzaldehyde	>95	>95	91	91	18m
14	3-Bromobenzaldehyde	>95	>95	88	88	18n
15	4-Bromobenzaldehyde	89	89	90	97	180
16	3-Cyanobenzaldehyde	90	92	89	96	18p
17	4-Cyanobenzaldehyde	94	93	93	92	18q

^{a)} All the experiments were performed under identical conditions (6h).^{b)} Chemical yields are referred to isolated compounds

Conclusions

In conclusion, we have designed and fine-tuned new, efficient, optically active β -amino alcohol ligands, the chirality of which arises from the Sharpless epoxidation of suitable allyl alcohols. After optimizing the structures of **13a** and **13b** by employing the well-established enantioselective amino alcohol-promoted addition of diethylzinc to benzaldehyde, their broad applicability as chiral catalysts was evaluated by carrying out the same reaction on a family of aldehydes, including variously substituted aromatic ones as well as an aliphatic analogue. The results confirmed the validity of the fine-tuning process performed on ligands **13a** and **13b**. In fact, both exhibited excellent catalytic activity as demonstrated by the chemical yields and *ee* obtained from all the tested aldehydes, almost independent of the position and type of substitution in the aromatic ring.

In light of the reported results, we are currently investigating the catalytic efficiency of **13a** and **13b** in other reactions

catalysed by amino alcohols, as well as the immobilization of the ligands on magnetite nanoparticles.

Experimental Section

General methods and materials

All anhydrous reactions were carried out in flame-dried glassware under argon atmosphere. Unless otherwise stated, commercial reagents were used without further purification. All chromatographic purifications were performed on silica gel (230-400 mesh). Thin layer chromatography (TLC) was performed on pre-coated silica gel 60 F254 plates and visualization was achieved by inspection under UV light (Mineralight UVG 11 254 nm) followed by staining with phosphomolybdic acid dip [polyphosphomolybdic acid (12 g), ethanol (250 mL)] or Ninhydrin dip [ninhydrin (5 g), sulfuric acid (5 mL), *n*-butanol (100mL)]. Organic solvents used for the chemical synthesis and for chromatography were of analytical grade. Benzaldehyde was freshly distilled before use. For all known compounds the spectral characteristics were in agreement with those reported in the literature. NMR spectra

were recorded using a Varian Mercury 300 (¹H-NMR 300 MHz and ¹³C-NMR 75 MHz) and chemical shifts are reported in ppm using the residual solvent peak as a reference. Analytical high performance liquid chromatography (HPLC) was performed using the indicated chiral column. Optical rotations were measured on a digital polarimeter Jasco DIP-370 with a cell path length of 1 cm at 589 nm; solution concentrations are reported in grams per 100 ml. Elemental analyses for C, H, and N were performed on an EA 1110 CHNS-O Instrument.

Synthesis of amino alcohol ligands

ARTICLE

The following compounds were prepared following already known procedures^{§§§§} and all experimental data were consistent with the ones reported in the literature 5a,¹⁸ 5b,¹⁹ 5c,¹⁸ 12a,¹⁵ 15a,²⁰ 15b²⁰

General procedure for the preparation of compounds 6a, 6b, 6c: The epoxy alcohol (5a or 5b or 5c) (1 mmol) was dissolved in CCI_4 (2 mL), CH_3CN (2 mL) and phosphate buffer (pH = 7, 0.2 M, 3 mL) with vigorous stirring. Then NaIO₄ (2.8 mmol, 600 mg) and RuCl₃ (0.05 mmol, 10 mg) were added. After 12 h, CH₂Cl₂ and water were added. The organic layer was separated and the aqueous layer was extracted several times with CH₂Cl₂. The combined organic extracts were dried, concentrated and then filtered on a celite pad. The solvent was removed in vacuo affording the crude carboxylic acid. The crude product was dissolved in CH₂Cl₂ (5 mL) and allyl amine (1.1 mmol, 0,08 ml) was added. The solution was added to a solution of 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (170 mg, 1.1 mmol) and 1-Hydroxy-7-azabenzotriazole (136 mg, 1 mmol) in CH₂Cl₂ (5 mL) and the reaction was stirred at room temperature for 2 hours. CH_2Cl_2 and water were added. The organic layer was separated and the aqueous layer was extracted three times with CH₂Cl_{2.} The combined organic extracts were washed with brine, dried and concentrated in vacuo. The crude material was purified by flash chromatography using hexane/EtOAc 70:30 as eluent.

(2*R*,3*S*)-*N*-allyl-3-propyloxirane-2-carboxamide (6a): obtained from **5a**, 130 mg, 75%, pale yellow oil; ¹H-NMR (300 MHz, CDCl₃) δ : 6.25 (bs, 1H), 5.83-5.66 (m, 1H), 5.16-5.02 (m, 2H), 3.85-3.74 (m, 2H), 3.19 (d, 1H, *J* = 1.9 Hz), 2.94-2.86 (m, 1H), 1.68-1.36 (m, 4H), 0.93 (t, 3H, *J*=7.0 Hz); ¹³C-NMR (75 MHz, CDCl₃) δ : 168.2, 133.4, 116.1, 59.1, 55.0, 40.8, 33.4, 18.7, 13.4; Anal. Calcd for C₉H₁₅NO₂: C, 63.88; H, 8.93; N, 8.28. Found: C, 64.03; H, 8.95; N, 8.29.

(2*R*,3*S*)-*N*-allyl-3-phenyloxirane-2-carboxamide (6c): obtained from 5c, 107.7 mg, 53%, pale yellow oil; ¹H-NMR (300 MHz, CDCl₃) δ : 7.81-7.68 (d, 1H, *J* = 7.2 Hz), 7.53-7.09 (m, 4H), 6.35 (bs, 1H), 6.00-5.72 (m, 1H), 5.30-4.99 (m, 2H), 4.16-3.95 (m, 2H), 3.95-3.77 (m, 1H), 3.55-3.40 (m, 1H); ¹³C-NMR (75 MHz, CDCl₃) δ : 167.2, 133.3, 131.2, 128.8, 128.4, 128.2, 126.8, 125.6, 116.5, $\begin{array}{l} {\sf 58.7, 42.2, 41.1. Anal. Calcd for C_{12}H_{13}NO_2: C, 70.92 \\ {\sf W}_{rc} {\sf 6.45}_{rl} {\sf N}_{e} \\ {\sf 6.89. Found: C, 71.15; H, 6.48; N, 6.92. } \\ {\sf DOI: 10.1039/C8OB00165K} \end{array}$

General procedure for the preparation of compounds 1 and 2: In a sealed tube epoxy amide **6a** (169 mg, 1 mmol) was placed and treated with aq 33% NH₄OH (10 mL). After two days with stirring at 60 °C the reaction mixture was concentrated *in vacuo* to give a pale yellow oil. The crude material was purified by flash chromatography (chloroform/methanol 92:8) giving **1**, 65 mg, 35% and **2**, 69 mg, 37%.

(25,35)-N-allyl-2-amino-3-hydroxyhexanamide 1: $[\alpha]^{25}_{D}$ = -7.8 (c=1.6 in CH₃OH); ¹H-NMR (300 MHz, CDCl₃) δ : 7.62 (bt, 1H, J= 5.6 Hz), 5.83-5.67 (m, 1H), 5.17-5.01 (m, 2H), 3.83-3.70 (m, 3H), 3.31 (d, 1H, J= 5.4 Hz), 2.89-2.71 (bs, 3H), 1.53-1.21 (m, 4H), 0.83 (t, J=7.1 Hz); ¹³C-NMR (75 MHz, CDCl₃) δ : 173.9, 133.9, 116.2, 72.7, 59.2, 41.4, 34.2, 18.8, 14.0; Anal. Calcd for C₉H₁₈N₂O₂: C, 58.04; H, 9.74; N, 15.04. Found: C, 58.25; H, 9.75; N, 15.08.

(2*R*,3*R*)-*N*-allyl-3-amino-2-hydroxyhexanamide 2: $[\alpha]^{25}_{D}$ = 31.1 (c=3.3 in CH₃OH); ¹H-NMR (300 MHz, CDCl₃) δ : 7.48 (bt, 1H, *J*=6.0 Hz), 5.86-.71 (m, 1H), 5.20-5.05 (m, 2H), 4.01 (d, 1H, *J*=4.1 Hz), 3.89-3.80 (m, 2H), 3.50-3.20 (bs, 3H), 3.15-3.06 (m, 1H), 1.46-1.14 (m, 4H), 0.86 (t, 3H, *J*=6.5 Hz); ¹³C-NMR (75 MHz, CDCl₃) δ : 172.7, 134.0, 116.3, 74.2, 53.6, 41.3, 33.6, 19.3, 14.1; Anal. Calcd for C₉H₁₈N₂O₂: C, 58.04; H, 9.74; N, 15.04. Found: C, 58.28; H, 9.85; N, 15.18.

(25,3*R*)-*N*-allyl-3-bromo-2-hydroxyhexanamide 7: To a solution of compound **6a** (169 mg, 1 mmol) in Et₂O (15 mL) at -20°C under argon, MgBr₂·OEt₂ (390 mg, 1.5 mmol) was added and the mixture was stirred for 12 h. The mixture was diluted with Et₂O and washed with water and brine. The organic layer was dried and concentrated *in vacuo*. The crude material was purified by flash chromatography (hexane/EtOAc 70:30) affording **7**. 182 mg, 73%, yellowish; $[\alpha]^{25}_{D}$ = 51.3 (c=3.6 in CHCl₃); ¹H-NMR (300 MHz, CDCl₃) δ : 7.06 (bs, 1H), 5.88-5.68 (m, 1H), 5.23-5.03 (m, 2H), 4.53-4.30 (m, 2H), 4.05 (d, 1H, J=4.4 Hz), 3.90-3.81 (m, 2H), 1.88-1.70 (m, 1H), 1.62-1.45 (m, 2H), 1.44-1.25 (m, 1H), 0.88 (t, J=6.9 Hz); ¹³C-NMR (75 MHz, CDCl₃) δ : 169.8, 133.4, 116.7, 76.0, 59.1, 41.4, 33.9, 21.1, 13.2; Anal. Calcd for C₉H₁₆BrNO₂: C, 43.22; H, 6.45; N, 5.60. Found: C, 43.35; H, 6.45; N, 5.65.

(2*R*,3*S*)-*N*-allyl-3-azido-2-hydroxyhexanamide 8: A solution of compound 7 (250 mg, 1 mmol), NaN₃ (260, 4 mmol) and 18-crown-6 (135 mg, 0.51 mmol) in DMSO (1.0 mL) was stirred at 65 °C under argon for 12 h. The mixture was diluted with Et₂O and washed several times with water and brine. The organic layer was then dried and concentrated *in vacuo*. Chromatographic purification (hexane/EtOAc 70:30) afforded 8. 187 mg, 88%, pale yellow oil, $[\alpha]^{25}$ _D= 24.5 (c=3.6 in CHCl₃); ¹H-NMR (300 MHz, CDCl₃) δ : 7.17 (bs, 1H), 5.89-5.70 (m, 1H), 5.25-5.08 (m, 2H), 4.70 (d, 1H, *J*=6.2 Hz), 4.10 (d, 1H, *J*=3.9 Hz), 3.92-3.80 (m, 2H), 3.72-3.64 (m, 1H), 1.77-1,33 (m, 4H), 0.93 (t, 3H, *J*= 6.5 Hz); ¹³C-NMR (75 MHz, CDCl₃) δ : 172.1, 133.3, 116.3, 73.5, 62.9, 41.5, 32.3, 19.3, 13.6; Anal. Calcd for C₉H₁₆N₄O₂: C, 50.93; H, 7.60; N, 26.40. Found: C, 51.09; H, 7.65; N, 26.48.

(2R,3S)-N-allyl-3-amino-2-hydroxyhexanamide 3: To a solution of 8 (186 mg, 1 mmol) in MeOH (15 ml) H_2O (1.5 ml) and PPh₃ (393 mg, 1.5 mmol) were added and allowed to stirred at room temperature for 12 h. Methanol was then evaporated and the aqueous layer extracted with CHCl₃. The organic layer was dried

Published on 14 February 2018. Downloaded by Kocaeli Universitesi on 15/02/2018 14:16:49.

Journal Name

and concentrated *in vacuo*. The crude product was purified by flash chromatography (CHCl₃/MeOH 98:2) giving **3**, 126.6 mg, 68%, pale yellow oil; $[\alpha]^{25}_{D}$ = 12.5 (c=2.6 in CHCl₃); ¹H-NMR (300 MHz, CDCl₃) δ : 7.01 (bs, 1H), 5.90-5.67 (m, 1H), 5.24-5.01 (m, 2H), 3.96 (m, 3H), 3.28-3.15 (m, 1H), 1.64-1.15 (m, 4H), 0,88 (t, 3H, J= 7.3 Hz); ¹³C-NMR (75 MHz, CDCl₃) δ : 173.4, 136.9, 115.8, 73.4, 52.7, 41.1, 35.5, 19.3, 13.8; Anal. Calcd for C₉H₁₈N₂O₂: C, 58.04; H, 9.74; N, 15.04. Found: C, 58.18; H, 9.81; N, 15.15.

General procedure for the preparation of compounds 9, 10, 11: A mixture of the substrate (1 or 2 or 3) (1.0 mmol), *n*-propyl iodide (0,194 ml, 2.0 mmol), K_2CO_3 (276 mg, 2.0 mmol) and CH₃CN (5 mL) was refluxed for 48 h. The reaction mixture was cooled to room temperature and filtered. The filtrate was concentrated *in vacuo* and the residue was purified by flash chromatography (CHCl₃/MeOH 98:2).

(2*R*,3*R*)-*N*-allyl-3-(dipropylamino)-2-hydroxyhexanamide 10: obtained from 2, 189.3 mg, 70%, pale yellow oil; ¹H-NMR (300 MHz, CDCl₃) δ : 7.75 (bs, 1H), 5.85-5.66 (m, 1H), 5.20-5.02 (m, 2H), 4.53 (bs, 1H), 3.90 (d, 1H, *J* = 7.4 Hz), 3.84-3.75 (m, 2H), 2.82-2.73 (m, 1H) 2.36-2.28 (m, 4H), 1.60-1.19 (m, 8H), 0.87 (t, 3H, J = 7.4 Hz), 0.77 (t, 6H, J = 7.3 Hz); ¹³C-NMR (75 MHz, CDCl₃) δ : 173.5, 133.9, 116.6, 68.8, 63.8, 53.3, 41.6, 27.5, 22.3, 21.2, 14.4, 11.7; Anal. Calcd for C₁₅H₃₀N₂O₂: C, 66.62; H, 11.18; N, 10.36. Found: C, 66.83; H, 11.22; N, 10.44.

 $\begin{array}{l} \textbf{(2R,3S)-N-allyl-3-(dipropylamino)-2-hydroxyhexanamide} \quad \textbf{11:}\\ obtained from \textbf{3}, 148.7, 55\%, pale yellow oil; ^1H-NMR (300 MHz, CDCl_3) & 5.7.49 (bs, 1H), 5.90-5.70 (m, 1H), 5.23-5.01 (m, 2H), 3.96 (d, 1H, J = 2.6 Hz), 3.91-3.80 (m, 2H), 3.15-3.04 (m, 2H) 2.73-2.49 (m, 4H), 1.78-1.32 (m, 8H), 0.96-0.81 (m, 9H); ^{13}C-NMR (75 MHz, CDCl_3) & 173.5, 133.7, 116.2, 69.6, 59.3, 49.6, 41.2, 33.5, 22.8, 19.4, 13.8, 11.3; Anal. Calcd for C_{15}H_{30}N_2O_2: C, 66.62; H, 11.18; N, 10.36. Found: C, 66.85; H, 11.21; N, 10.40. \end{array}$

General procedure for the preparation of compounds 12a-g: A mixture of the epoxy amide (6a or 6b or 6c) (1.0 mmol), amine (excess, 1 mL) and Ti(O-*i*Pr)₄ (1.5 mmol, 0,448 ml) was stirred at room temperature for 12 h. After this time, EtOAc was added and the organic layer was washed with an aqueous tartaric acid solution (0.5 M), dried and concentrated *in vacuo*. The crude product was purified by flash chromatography (CH₂Cl₂/MeOH, 95:5, 0.2% NH₄OH).

(2R,3R)-N-allyl-3-cyclohexyl-3-(dipropylamino)-2-

hydroxypropanamide 12b: obtained from **6b** and Pr₂NH, 279.2, 90%, colorless oil; ¹H-NMR (300 MHz, CDCl₃) δ: 7.31 (bs, 1H), 5.89-5.68 (m, 1H), 5.26-5.03 (m, 2H), 4.12 (d, 1H, *J* = 4.9 Hz), 3.94-3.73 (m, 2H), 2.72-2.39 (m, 5H),), 2.31-2.12 (m, 1H), 1.93-0.87 (m, 15H), 0.82 (t, 6H, *J* = 7.4 Hz); ¹³C-NMR (75 MHz, CDCl₃) δ: 173.3, 134.0, 116.7, 71.2, 67.5, 55.2, 41.5, 37.4, 32.7, 30.8, 26.5, 26.2, 25.9, 23.7, 11.5; Anal. Calcd for C₁₈H₃₄N₂O₂: C, 69.63; H, 11.04; N, 9.02. Found: C, 69.81; H, 11.09; N, 9.06.

ARTICLE

(2R,3R)-N-allyl-3-cyclohexyl-3-(dibutylamino)-2- View Article Online

hydroxypropanamide 12c: obtained fro P**6b** and BUMP/9522 mg, >95%, colorless oil; ¹H-NMR (300 MHz, CDCl₃) δ: 7.33 (bs, 1H), 5.87-5.71 (m, 1H), 5.23-5.06 (m, 2H), 4.83 (bs, 1H), 4.16-4.06 (m, 1H), 3.93-3.71 (m, 2H), 2.70-2.42 (m, 4H), 2.23-2.14 (m, 1H), 1.84-1.13 (m, 19H), 0.87 (t, 6H, J = 7.5 Hz); ¹³C-NMR (75 MHz, CDCl₃) δ:173.3, 133.9, 116.7, 70.9, 67.5, 53.0, 41.5, 37.4, 32.7, 30.8, 26.5, 26.2, 25.9, 20.4, 14.0; Anal. Calcd for C₂₀H₃₈N₂O₂: C, 70.96; H, 11.31; N, 8.28. Found: C, 71.21; H, 11.37; N, 8.30.

(2R,3R)-N-allyl-3-cyclohexyl-2-hydroxy-3-(piperidin-1-

yl)propanamide 12d: obtained from **6b** and piperidine, 280 mg, >95%, colorless oil; ¹H-NMR (300 MHz, CDCl₃) δ : 7.67 (bs, 1H), 5.84-5.68 (m, 1H), 5.20-5.00 (m, 2H), 4.58 (bs, 1H), 4.04 (d, 1H, J = 5.7 Hz), 3.89-3.67 (m, 2H), 2.75-2.46 (m, 4H), 2.41 (dd, 1H, J = 8.5, 6.4 Hz), 2.08-1.97 (m, 1H), 1.83-0.94 (m, 16H); ¹³C-NMR (75 MHz, CDCl₃) δ : 173.4, 133.9, 116.2, 73.5, 67.1, 51.4, 51.3, 41.2, 36.6, 32.7, 30.2, 26.9, 26.3, 26.1, 25.8, 24.3; Anal. Calcd for C₁₇H₃₀N₂O₂: C, 69.35; H, 10.27; N, 9.51. Found: C, 69.60; H, 10.30; N, 9.55.

(2R,3R)-N-allyl-3-cyclohexyl-2-hydroxy-3-

morpholinopropanamide 12e: obtained from **6b** and morpholine, 257.8 mg, 87%, colorless oil; ¹H-NMR (300 MHz, CDCl₃) δ: 7.48 (bt, 1H, *J* = 5.3 Hz), 5.84-5.67 (m, 1H), 5.20-5.05 (m, 2H), 4.15 (d, 1H, *J* = 4.4 Hz), 3.90-3.75 (m, 2H), 3.65-3.52 (m, 4H), 2.78-2.57 (m, 4H), 2.53 (dd, 1H, *J* = 9.0, 4.4 Hz), 2.08-1.82 (m, 3H), 1.72-1.55 (m, 3H), 1.30-0.92 (m, 5H); ¹³C-NMR (75 MHz, CDCl₃) δ: 173.4, 133.8, 116.5, 72.7, 67.6, 50.5, 41.3, 36.1, 32.2, 30.2, 26.3, 26.0, 25.9; Anal. Calcd for C₁₆H₂₈N₂O₃: C, 64.83; H, 9.52; N, 9.45. Found: C, 65.05; H, 9.56; N, 9.48.

(2R,3R)-N-allyl-3-(dibutylamino)-2-hydroxy-3-

phenylpropanamide 12f: obtained from **6c** and Bu₂NH, 315 mg, >95%, colorless oil; ¹H-NMR (300 MHz, CDCl₃) δ : 7.57 (bs, 1H), 7.30-7.15 (m, 5H), 5.55-5.39 (m, 1H), 5.00-4.83 (m, 2H), 4.44 (d, 1H, J = 7.1 Hz), 3.91 (d, 1H, J = 7.1 Hz), 3.70 (ddt, 2H, *J* = 15.7, 6.0, 1.3, Hz), 3.55 (ddt, 2H, *J* = 15.7, 5.5, 0.3 Hz), 2.61-2.47 (m, 2H), 2.36-2.22 (m, 2H), 1.44-1.31 (m, 4H), 1.28-1.08 (m, 4H), 0.81 (t, 6H, *J* = 7.3 Hz); ¹³C-NMR (75 MHz, CDCl₃) δ : 172.1, 135.4, 133.9, 129.6, 127.8, 127.6, 116.3, 69.3, 67.4, 49.8, 41.4, 28.9, 20.6, 13.9; Anal. Calcd for C₂₀H₃₂N₂O₂: C, 72.25; H, 9.70; N, 8.43. Found: C, 72.54; H, 9.74; N, 8.46.

(2R,3R)-N-allyl-2-hydroxy-3-phenyl-3-(piperidin-1-

yl)propanamide 12g: obtained from **6c** and piperidine, 275 mg, >95%, colorless oil; ¹H-NMR (300 MHz, CDCl₃) δ: 7.89 (bs, 1H), 7.38-6.96 (m, 5H), 5.66-5.40 (m, 1H), 5.05-4.80 (m, 2H), 4.58 (d, 1H, J = 7.3 Hz), 4.10 (bs, 1H), 3.76-3.56 (m, 2H), 3.66 (d, 1H, J = 7.3 Hz), 2.60-2.20 (m, 4H), 1.63-1.21 (m, 6H); ¹³C-NMR (75 MHz, CDCl₃) δ: 172.3, 133.9, 129.3, 127.8, 127.6, 116.2, 71.6, 68.3, 51.4, 41.3, 26.3, 26.2, 24.2; Anal. Calcd for C₁₇H₂₄N₂O₂: C, 70.80; H, 8.39; N, 9.71. Found: C, 71.07; H, 8.42; N, 9.75.

(2*R*,3*S*)-3-phenyloxirane-2-carbaldehyde 15c: To a stirred solution of epoxy alcohol 5c (150 mg, 1 mmol) in CH_2Cl_2 (8 ml) at 0°C, Et₃N (0.56 ml, 3.8 mmol) and PySO₃ (478 mg, 3 mmol) in DMSO (3 ml) were added. The mixture was stirred at room temperature for 12 h. Then the mixture was diluted with 20 ml of Et₂O and 40 ml of hexane, washed with NaHCO₃ s.s.; the aqueous layer was extracted with a mixture 1:2.8 Et₂O/hexane

ARTICLE

and the organic layer washed with NaHPO₄ 1 M, and brine then dried and concentrated in vacuo. The crude material was purified by flash chromatography (hexane/EtOAc 85:25) giving **15c** , 120 mg, 81%, colorless oil; ¹H-NMR (300MHz, CDCl₃) δ : 9.20 (d, 1H, J = 6.0 Hz), 7.48-7.18 (m, 5H), 4.16 (d, 1H, J = 1.5 Hz), 3.44 (dd, 1H, J = 6.0, 1.5 Hz). ¹³C-NMR (75 MHz, CDCl₃) δ: 196.7, 134.1, 129.1, 128.7, 125.6, 62.8, 56.6. Anal. Calcd for C₉H₈O₂: C, 72.96; H, 5.44. Found: C, 72.99; H, 5.47.

General procedure for the preparation of compounds 17a-c: A solution of aldehyde (15a or 15b or 15c) (1 mmol) in THF dry (8.0 ml) was added dropwise to a stirred solution of *n*-BuLi (1.5 mL of a 1.6 M hexane solution, 2.4 mmol) and diethylphosphonoacetic acid (0.2 mL, 1.1 mmol) in THF dry (1.5 mL) under an argon atmosphere at -70°C. After 2 hours the reaction mixture was allowed to reach the room temperature and then stirred for 12 hours. 0.1 M HCl aqueous solution was added until pH 2 and the aqueous layer was extracted several times with Et₂O. The combined organic extracts were dried and concentrated in vacuo affording the crude carboxylic acid 16ac. The crude product was dissolved in CH₂Cl₂ (5 mL) and allyl amine (1.1 mmol, 0,08 ml) was added. The solution was added solution of 1-Ethyl-3-(3-dimethylaminopropyl)to а carbodiimide (170 mg, 1.1 mmol) and 1-Hydroxy-7azabenzotriazole (136 mg, 1 mmol) in CH₂Cl₂ (5 mL) and the reaction was stirred at room temperature for 2 hours. CH₂Cl₂ and water were added. The organic layer was separated and the aqueous layer was extracted three times with CH_2Cl_2 . The combined organic extracts were washed with brine, dried and concentrated in vacuo. The crude material was purified by flash chromatography (hexane/EtOAc 70:30).

(E,2S,3S)-N-allyl-3-(3-propyloxiran-2-yl)acrylamide 17a: obtained from 16a, 130.8 mg, 67% from 15a, colorless oil; ¹H-NMR (300 MHz, CDCl₃): δ 6.58 (dd, 1H, J = 15.3, 6.7 Hz), 6.44 (bs, 1H), 6.14 (d, 1H, J = 15.3 Hz), 5.86-5.72 (m, 1H), 5.14-4.98 (m, 2H), 3.88 (bt, 2H, J=5.7 Hz), 3.16 (dd, 1H, J = 6.7, 1.8 Hz), 2.81 (ddd, 1H, J₁=J₂=5.2, 1.9 Hz), 1.59-1.37 (m, 4H), 0.91 (t, J = 7.2 Hz, 3H); ¹³C-NMR (75 MHz, CDCl₃): δ 164.8, 140.4, 133.8, 125.5, 116.3, 61.4, 56.4, 41.9, 33.8, 19.0, 13.7; Anal. Calcd for C₁₁H₁₇NO₂: C, 67.66; H, 8.78; N, 7.17. Found: C, 67.91; H, 8.80; N, 7.18.

(*E*,2*S*,3*S*)-*N*-allyl-3-(3-cyclohexyloxiran-2-yl)acrylamide 17b: obtained from 16b, 97.4 mg, 72% from 15b, colorless oil; ¹H-NMR (300 MHz, CDCl₃) δ : 6.71 (bs, 1H), 6.54 (dd, 1H, J = 15.2, 6.6 Hz), 6.14 (d, 1H, J = 15.2 Hz), 5.83-5.68 (m, 1H), 5.10 (bd, 1H, J = 17.2 Hz), 5.04 (bd, 1H, J = 10.3 Hz), 3.84 (bt, 2H, J = 4.9 Hz), 3.23 (bd, 1H, J = 6.6 Hz), 2.60 (bd, 1H, J = 6.5 Hz), 1.81-1.53 (m, 5H),1.30-0.91 (m, 6H); ¹³C-NMR (300 MHz, CDCl₃) δ: 164.8, 140.5, 133.8, 125.4, 116.1, 65.7, 55.1, 41.8, 39.8, 29.3, 28.6, 26.0, 25.4, 25.3; Anal. Calcd for C₁₄H₂₁NO₂: C, 71.46; H, 8.99; N, 5.95. Found: C, 71.73; H, 9.00; N, 5.97.

(E,2S,3S)-N-allyl-3-(3-phenyloxiran-2-yl)acrylamide 17c: obtained from 16c,149 mg, 65% from 15c, colorless oil; ¹H-NMR (300 MHz, CDCl₃) δ: 7.41-7.23 (m, 5H), 6.78 (dd, 1H, J = 15.3, 6.3 Hz), 6.19 (d, 1H, J = 15.3 Hz), 5.97 (bs, 1H), 5.93-5.79 (m, 1H), 5.19 (dd, 1H, J = 17.3, 1.3 Hz), 5.14 (dd, 1H, J = 10.3, 1.3 Hz), 3.95 (bt, 2H, J = 5.7 Hz), 3.78 (d, 1H, J = 1.5 Hz), 3.46 (dd, 1H, J = 6.3, 1.5 Hz). ¹³C-NMR (75 MHz, CDCl₃) δ: 164.5, 139.7, 136.2, 133.8,

128.6, 128.5, 125.7, 125.4, 116.6, 61.2, 60.7, 42.0; Anal. Calcd for C14H15NO2: C, 73.34; H, 6.59; N, 6.12.0Fd0A089C,8738.604;6FK, 6.62; N, 6.15.

General procedure for the preparation of compounds 13a-f, 14: The epoxy amide (17a or 17b or 17c) (1 mmol), LiClO₄ (1.59 g, 15 mmol), and the selected amine (10 mmol, excess) in acetonitrile (3 mL) were stirred at 55 °C for 24 h. Then H₂O was added, and the aqueous layer was extracted with CH₂Cl₂. The combined organic extracts were dried, concentrated in vacuo and purified by flash chromatography (CH₂Cl₂/MeOH 95:5).

(E,4R,5S)-N-allyl-5-cyclohexyl-4-(dibutylamino)-5-

hydroxypent-2-enamide 13a: obtained from 17b and Bu₂NH, 262.5 mg, 72%, colorless oil; [α]²⁵_D= -16.5 (c=3.6 in CHCl₃); ¹H-NMR (300 MHz, CDCl₃) δ : 6.70 (dd, 1H, J = 15.4, 9.5 Hz), 6.38 (bs, 1H), 5.91 (d, 1H, J = 15.4 Hz), 5.87-5.70 (m, 1H), 5.13 (bd, 1H, J = 17.2 Hz), 5.06 (bd, 1H, J = 10.9 Hz), 3.87 (bt, 2H, J = 4.8 Hz), 3.39 (bt, 1H, J = 6.2 Hz), 3.09 (dd, 1H, J = 9.5, 6.2 Hz), 3.00 (bs, 1H), 2.52-2.26 (m, 4H), 1.82-1.40 (m, 6H), 1.40-0.90 (m, 13H), 0.83 (t, 6H, J = 7.1 Hz); ¹³C-NMR (300 MHz, CDCl₃) δ : 165.2, 140.3, 134.0, 127.3, 116.2, 74.4, 64.5, 50.3, 41.8, 38.8, 29.8, 29.3, 27.3, 26.4, 26.1, 25.8, 20.3, 13.9; Anal. Calcd for C₂₂H₄₀N₂O₂: C, 72.48; H, 11.06; N, 7.68. Found: C, 72.73; H, 11.09; N, 7.70.

(E,4R,5S)-N-allyl-5-cyclohexyl-5-hydroxy-4-morpholinopent-2enamide 13b: obtained from 17b and morpholine, 251.5 mg, 78%, colorless oil; $[\alpha]^{25}_{D} = -27.2$ (*c* 3.2, CHCl₃); ¹H-NMR (300 MHz, CDCl₃) δ: 6.74 (dd, J = 15.7, 9.9 Hz, 1H), 5.96 (d, J = 15.7 Hz, 1H), 5.92-5.78 (m, 1H), 5.72 (bs, 1H), 5.26-5.11 (m, 2H), 3.96 (bt, 2H, J = 5.7 Hz), 3.69 (bt, 4H, J = 4.4 Hz), 3.53 (dd, 1H, J = 8.5, 3.0 Hz), 3.20 (bs, 1H), 2.89 (dd, 1H, J = 9.8, 3.0 Hz), 2.65-2.41 (m, 4H), 2.03 (bd, 1H, J = 11.9 Hz), 1.78-1.48 (m, 4H), 1.41-0.76 (m, 6H); ¹³C-NMR (75 MHz, CDCl₃) δ: 164.6, 139.2, 133.9, 127.9, 116.8, 72.3, 68.9, 67.0, 51.6, 42.0, 39.4, 29.5, 27.9, 26.4, 25.6, 25.5; Anal. Calcd for C₁₈H₃₀N₂O₃: C, 67.05; H, 9.38; N, 8.69. Found: C, 67.30; H, 9.40; N, 8.70.

(E,4R,5S)-N-allyl-5-cyclohexyl-5-hydroxy-4-(piperidin-1-

yl)pent-2-enamide 13c: obtained from 17b and piperidine, 247 mg, 77%, colorless oil; $[\alpha]^{25}_{D}$ = - 27.3 (*c* 3.1, CHCl₃); ¹H-NMR (300 MHz, CDCl₃) δ: 6.71 (dd, J = 15.3, 9.5 Hz, 1H), 6.09 (s, 1H), 5.92 (d, 1H, J = 15.3 Hz), 5.92-5.75 (m, 1H), 5.23-5.05 (m, 2H), 3.92 (bt, 2H, J = 5.0 Hz), 3.48 (bd, 1H, J = 7.9 Hz), 3.20 (bs, 1H), 2.82 (bd, 1H, J = 9.5 Hz), 2.54-2.24 (m, 4H), 1.96 (bd, 1H, J = 12.4 Hz), 1.80-0.75 (m, 16H); ¹³C-NMR (75 MHz, CDCl₃) δ: 165.0, 140.1, 134.0, 127.1, 116.5, 72.9, 68.9, 52.1, 42.0, 39.3, 29.2, 28.0, 26.4, 26.2, 25.7, 25.6, 24.4; Anal. Calcd for C₁₉H₃₂N₂O₂: C, 71.21; H, 10.06; N, 8.74. Found: C, 71.50; H, 10.12; N, 8.77.

(E,4R,5S)-N-allyl-4-(dibutylamino)-5-hydroxyoct-2-enamide

13d: obtained from 17a and Bu₂NH, 237 mg, 73%, colorless oil; $[\alpha]^{25}_{D}$ = - 13.5 (*c* 2.7, CHCl₃); ¹H-NMR (300 MHz, CDCl₃) δ : 6.79 (dd, 1H, J = 15.5, 9.7 Hz), 5.91 (d, 1H, J = 15.5 Hz), 5.92-5.76 (m, 2H), 5.24-5.11 (m, 2H), 3.95 (bt, 2H, J = 5.7 Hz), 3.75-3.64 (m, 1H), 3.03 (dd, 1H, J = 9.6, 5.6 Hz), 2.81 (bs, 1H), 2.61-2.32 (m, 4H), 1.59-1.05 (m, 12 H), 0.89 (t, 9H, J = 7.1 Hz); ¹³C-NMR (75 MHz, CDCl₃): δ 164.9, 140.2, 134.0, 127.6, 116.7, 70.4, 67.6, 50.9, 42.0, 35.9, 29.9, 20.4, 19.2, 14.1, 14.0; Anal. Calcd for C19H36N2O2: C, 70.32; H, 11.18; N, 8.63. Found: C, 70.58; H, 11.20; N, 8.65.

(*E*,4*R*,5*S*)-*N*-allyl-5-hydroxy-4-morpholinooct-2-enamide 13e: obtained from 17a and morpholine, 237 mg, 84%, colorless oil; $[\alpha]^{25}_{D} = -38.0$ (*c* 2.9, CHCl₃); ¹H-NMR (300 MHz, CDCl₃) δ : 6.72 (dd, 1H, *J* = 15.5, 9.9 Hz), 6.01 (bs, 1H), 5.94 (d, 1H, *J* = 15.5 Hz), 5.90-5.76 (m, 1H), 5.24-5.09 (m, 2H), 3.99-3.82 (m, 3H), 3.69 (t, 4H, *J* = 4.5 Hz), 3.11 (bs, 1H), 2.70 (dd, 1H, *J* = 9.8, 3.3 Hz), 2.64-2.42 (m, 4H), 1.57-1.19 (m, 4H), 0.89 (t, 3H, *J* = 6.8 Hz); ¹³C-NMR (75 MHz, CDCl₃) δ : 164.6, 139.2, 133.9, 128.3, 116.7, 71.6, 68.4, 67.0, 51.5, 42.0, 35.8, 19.1, 14.0; Anal. Calcd for C₁₅H₂₆N₂O₃: C, 63.80; H, 9.28; N, 9.92. Found: C, 64.02; H, 9.30; N, 9.95.

(4R,5S,E)-N-allyl-5-hydroxy-4-morpholino-5-phenylpent-2-

enamide 13f: obtained from **17c** and morpholine, 66,4 mg, 21%, pale yellow oil; $[\alpha]^{25}_{D} = 35.0$ (*c* 1.8, CHCl₃); ¹H-NMR (300 MHz, CDCl₃) δ : 7.33-7.20 (m, 5H), 6.68 (dd, 1H, *J* = 15.5, 9.8 Hz), 5.85-5.71 (m, 1H), 5.46 (d, 1H, *J* = 15.5 Hz), 5.39 (bt, 1H, *J* = 5.2 Hz), 5.20-5.06 (m, 3H), 3.85 (bt, 2H, *J* = 5.7 Hz), 3.75 (t, 4H, *J* = 4.6 Hz), 3.03 (dd, 1H, *J* = 9.8, 3.3 Hz), 2.77-2.60 (m, 4H); ¹³C-NMR (75 MHz, CDCl₃) δ : 164.3, 133.8, 130.1, 128.7, 128.1, 127.4, 126.1, 116.5, 73.4, 71.4, 66.8, 51.6, 41.8; Anal. Calcd for C₁₈H₂₄N₂O₃: C, 68.33; H, 7.65; N, 8.85. Found: C, 68.65; H, 7.67; N, 8.86.

(4S,5R,E)-N-allyl-4-hydroxy-5-morpholino-5-phenylpent-2-

enamide 14: obtained from **17c** and morpholine, 196 mg, 62%, pale yellow oil; $[\alpha]^{25}_{D} = -18.8$ (*c* 2.8, CHCl₃); ¹H-NMR (300 MHz, CDCl₃) δ : 7.33- 7.25 (m, 5H), 6.65 (dd, 1H, *J* = 15.2, 3.7 Hz), 5.89 (d, 1H, *J* = 15.2 Hz), 5.85-5.71 (m, 1H), 5.53 (bs, 1H), 5.15-5.04 (m, 2H), 4.93 (bs, 1H), 3.86 (bt, 2H, *J* = 5.5 Hz), 3.82-3.72 (m, 4H), 3.46 (bs, 1H), 2.74-2.49 (m, 4H); ¹³C-NMR (75 MHz, CDCl₃) δ : 165.1, 142.7, 135.2, 134.0, 129.3, 128.2, 128.1, 123.2, 116.2, 74.1, 68.6, 66.9, 51.6, 41.8; Anal. Calcd for C₁₈H₂₄N₂O₃: C, 68.33; H, 7.65; N, 8.85. Found: C, 68.67; H, 7.69; N, 8.85.

General procedure for the addition of diethylzinc to aldehydes: To a solution of the chiral amino alcohol (0.06 mmol, 6 mol%) toluene (2 mL) the aldehyde (1 mmol) was added at room temperature. The mixture was stirred for 20 min and then cooled to 0 °C. Diethylzinc (2.5 mL of a 1.0 M hexanes solution, 2.5 mmol) was added dropwise. Then the reaction mixture was allowed to reach the room temperature and stirred for the corresponding reaction time under argon. The reaction was quenched by the addition of a saturated NH₄Cl solution (10 mL). The mixture was then extracted with CH₂Cl₂. The combined organic extracts were dried and concentrated in vacuo. The product was purified by flash chromatography crude (hexane/EtOAc 90:10). Enantiomeric excesses were determined by HPLC analysis. Absolute configurations of the final alcohols were assigned by comparing the sign of the optical rotation or the retention time on HPLC with the literature value. The following data are related to the use of ligand 13b.

(S)-1-phenylpropan-1-ol 18a:²¹ 42 mg, > 95%; colorless oil; [α]²⁵_D = -47.2 (*c* 3.3, CHCl₃); *ee*=95% (HPLC: Chiralpack IB, hexane/i-PrOH 98:2, 0.9 mL/min, 258 nm, minor 12.1 min and major 12.4 min). ¹H-NMR (300 MHz, CDCl₃) δ: 7.65 - 7.21 (m, 5H), 4.54 (t, 1H, *J* = 6.6 Hz), 2.73 (bs, 1H), 1.86-1.67 (m, 2H), 0.91 (t, 3H, *J* = 7.4 Hz); ¹³C-NMR (75 MHz, CDCl₃) δ: 144.6, 128.4, 127.4, 126.0, 75.9, 31.9, 10.1.

(*S*)-1-(naphthalen-1-yl)propan-1-ol 18b:²² 178mg, > 95%; colorless oil; $[\alpha]^{25}_{D}$ = -62.0 (*c* 2.7, CHCl₃); *ee* = 97% (HPLC:

Chiralpack IA, hexane/i-PrOH 95:5, 1 mL/min, 220 nm, major, 8, 8 min and minor 9.7 min); ¹H-NMR (300 MP2/ CDCP3) δ: 82±108:50 (m, 1H), 7.88-7.78 (m, 1H), 7.78-7.68 (m, 1H), 7.61-7.52 (m, 1H), 7.52-7.35 (m, 3H), 5.32 (dd, 1H, *J* = 7.2, 5.2 Hz), 2.19 (bs, 1H), 2.05-1.78 (m, 2H), 0.98 (t, 3H, *J* = 7.4 Hz); ¹³C-NMR (75 MHz, CDCl₃) δ: 140.1, 133.7, 130.4, 128.8, 127.7, 125.8, 125.3, 125.3, 123.1, 122.8, 72.4, 31.0, 10.4.

(*E,S*)-1-phenylpent-1-en-3-ol 18c:²¹ 142.7 mg, 88%; colorless oil; $[\alpha]^{25}_{D}$ = -10.1 (*c* 2.5, CHCl₃); *ee* = 87.5% (HPLC: Chiralpack IC, hexane/i-PrOH 98:2, 1 mL/min, 254 nm, minor 13.0 min and major 14.9 min); ¹H-NMR (300 MHz, CDCl₃) δ : 7.43-7.17 (m, 5H), 6.57 (d, 1H, *J* = 15.9 Hz), 6.22 (dd, 1H, *J* = 15.9, 6.7 Hz), 4.21 (dd, 1H, *J* = 12.3, 6.2 Hz), 1.88 (bs, 1H), 1.74-1.55 (m, 2H), 0.97 (t, 3H, *J* = 7.4 Hz); ¹³C-NMR (75 MHz, CDCl₃) δ : 136.7, 132.2, 130.3, 128.5, 127.5, 126.4, 74.3, 30.2, 9.7.

(*S*)-1-(thiophen-3-yl)propan-1-ol 18d:²³ 135.7 mg, >95%; colorless oil; $[\alpha]^{25}_{D}$ = -33.0 (*c* 2.5, CHCl₃); *ee* = 94.7% (HPLC: Chiralpack IB, hexane/EtOH 99.6:0.4, 1.8 mL/min, 220 nm, minor 15.03 min and major 15.9 min); ¹H-NMR (300 MHz, CDCl₃) δ : 7.24 (dd, 1H, *J* = 4.9, 3.0 Hz), 7.12-7.05 (m, 1H), 7.02 (dd, 1H, *J* = 4.9, 1.2 Hz), 4.57 (t, 1H, *J* = 6.5 Hz), 3.18 (s, 1H), 1.80-1.63 (m, 2H), 0.88 (t, 3H, *J* = 7.4 Hz); ¹³C-NMR (75 MHz, CDCl₃) δ : 145.9, 125.6, 125.5, 120.5, 71.5, 30.9, 9.8.

(S)-1-cyclohexylpropan-1-ol 18e:²⁴ 125.2 mg, 88%; colorless oil; $[\alpha]^{25}_{D} = -8.6$ (*c* 1.9, CHCl₃); *ee* = 80.3% (HPLC on the *o*-bromo benzoyl ester derivative: Chiralpack IA, hexane/EtOH 99:1, 0.8 mL/min, 220 nm, minor 5.5 min and major 5.9 min); ¹H-NMR (300 MHz, CDCl₃) δ : 3.26 (ddd, 1H, *J* = 8.7, 5.4, 3.9 Hz), 1.87-0.98 (m, 16H), 0.94 (t, 3H, *J* = 7.4 Hz); ¹³C-NMR (75 MHz, CDCl₃) δ : 77.6, 43.1, 29.3, 27.7, 26.8, 26.5, 26.4, 26.2, 10.2.

(*S*)-1-(2-methoxyphenyl)propan-1-ol 18f:²² 160 mg, >95%; colorless oil; $[\alpha]^{25}_{D}$ = -22.1 (*c* 4.0, CHCl₃); *ee* = 95.7% (HPLC:Chiralpack IB, hexane/i-PrOH 97:3, 0.8 mL/min, 280 nm, major 10.9 min and minor 11.7 min); ¹H-NMR (300 MHz, CDCl₃) δ : 7.45 (d, 1H, *J* = 7.4 Hz), 7.23 (dd, 1H, *J*₁=*J*₂ = 7.7 Hz), 6.95 (dd, 1H, *J*₁=*J*₂ 7.4 Hz), 6.86 (d, 1H, *J* = 8.1 Hz), 4.82 (t, 1H, *J* = 6.5 Hz), 3.80 (s, 1H), 3.01 (bs, 1H), 1.80 (dq, 2H, *J*₁=*J*₂ 7.2 Hz), 0.96 (t, 3H, *J* = 7.3 Hz, CH₃). ¹³C-NMR (75 MHz, CDCl₃) δ 156.3, 132.3, 127.9, 126.8, 120.5, 110.2, 71.8, 55.0, 30.0, 10.3.

(*S*)-1-(3-methoxyphenyl)propan-1-ol 18g:²⁵ 100 mg, 60%; colorless oil; $[\alpha]^{25}_{D}$ = -30.9 (*c* 2.5, CHCl₃); *ee* = 97.4% (HPLC: Chiralpack IA, hexane/i-PrOH 95:5, 1 mL/min, 220 nm, minor 9.9 min and major 10.5 min; ¹H-NMR (300 MHz, CDCl₃) δ : 7.25 (t, 1H, *J* = 7.9 Hz), 6.89 (s, 1H), 6.81 (d, 2H, *J* = 7.5 Hz), 6.86 (d, 1H, *J* = 8.1 Hz), 4.55 (t, 1H, *J* = 6.5 Hz), 3.80 (s, 1H), 2.08 (bs, 1H), 1.86-1.65 (m, 2H), 0.91 (t, 3H, *J* = 7.4 Hz); ¹³C-NMR (75 MHz, CDCl₃) δ 159.6, 146.3, 129.3, 118.3, 112.8, 111.3, 75.8, 55.1, 31.8, 10.1.

(*S*)-1-(4-methoxyphenyl)propan-1-ol 18h:²² 159 mg, >95%; colorless oil; $[\alpha]^{25}_{D} = -45.1$ (*c* 3.3, CHCl₃); *ee* = 97% (HPLC: Chiralpack IA, hexane/i-PrOH 99.5:0.5, 1 mL/min, 274 nm, minor 54.6 min and major 61.0 min). ¹H-NMR (300 MHz, CDCl₃) δ : 7.22 (d, 2H, *J* = 8.5 Hz), 6.85 (d, 2H, *J* = 8.5 Hz), 4.47 (t, 1H, *J* = 6.7 Hz), 3.77 (s, 3H), 2.46 (bs, 1H), 1.85-1.60 (m, 2H), 0.86 (t, 3H, *J* = 7.3 Hz); ¹³C-NMR (75 MHz, CDCl₃) δ : 158.7, 136.7, 127.1, 113.6, 75.4, 55.1, 31.6, 10.1.

ARTICLE

(*S*)-1-(*o*-tolyl)propan-1-ol 18i:²² 142 mg, 95%; colorless oil; $[\alpha]^{25}_{D} = -54.5$ (*c* 4.4, CHCl₃); *ee* = 97.8% (HPLC: Chiralpack IA, hexane/i-PrOH 95:5, 0.8 mL/min, 220 nm, minor 7.6 min and major 8.3 min); ¹H-NMR (300 MHz, CDCl₃) δ : 7.46 (d, 1H, *J* = 7.4 Hz), 7.27-7.08 (m, 3H), 4.86 (t, 1H, *J* = 6.3 Hz), 2.34 (s, 3H), 1.82-1.68 (m, 3H), 0.98 (t, 3H, *J* = 7.3 Hz); ¹³C-NMR (75 MHz, CDCl₃) δ : 142.7, 134.6, 130.3, 127.1, 126.2, 125.2, 72.0, 30.9, 19.1, 10.4. (*S*)-1-(*m*-tolyl)propan-1-ol 18j:²⁶ 144 mg, >95%; colorless oil; $[\alpha]^{25}_{D} = -43.7$ (*c* 3.3, CHCl₃); *ee* = 98.6% (HPLC: Chiralpack IA, hexane/i-PrOH 99.5/0.5, 1.5 mL/min, 220 nm, minor 29.7 min and major 31.21 min); ¹H-NMR (300 MHz, CDCl₃) δ : 7.29-7.20 (m, 1H), 7.20-7.04 (m, 3H), 4.49 (t, 1H, *J* = 6.6 Hz), 2.92 (s, 1H), 2.40 (s, 3H), 1.88-1.66 (m, 2H), 0.94 (t, 3H, *J* = 7.4 Hz); ¹³C-NMR (75 MHz, CDCl₃) δ : 144.5, 137.6, 128.0, 127.9, 126.5, 122.9, 75.6, 31.6, 21.2, 10.0.

(*S*)-1-(*p*-tolyl)propan-1-ol 18k: ²⁶ 144 mg, >95%; colorless oil; $[\alpha]^{25}_{D} = -41.0$ (*c* 3.4, CHCl₃); *ee* = 97% (HPLC: Chiralpack IA, hexane/i-PrOH 98/2, 1 mL/min, 262 nm, minor 13.9 min and major 15.6 min); ¹H-NMR (300 MHz, CDCl₃) δ : 7.23 (d, 2H, *J* = 8.2 Hz), 7.17 (d, 2H, *J* = 8.2 Hz), 4.50 (t, 1H, *J* = 6.6 Hz), 2.73 (bs, 1H), 2.39 (s, 3H), 1.88-1.66 (m, 2H), 0.92 (t, 3H, *J* = 7.4 Hz); ¹³C-NMR (75 MHz, CDCl₃) δ : 141.5, 136.7, 128.8, 125.8, 75.5, 31.6, 20.9, 10.0.

(S)-1-(2-fluorophenyl)propan-1-ol 18I:²⁷ 135 mg, 88%; colorless oil; $[\alpha]^{25}_{D}$ = -32.3 (*c* 2.8, CHCl₃); *ee* = 90% (HPLC: Chiralpack IA, hexane/i-PrOH 98/2, 0.9 mL/min, 267 nm, minor 13.6 min and major 14.2 min); ¹H-NMR (300 MHz, CDCl₃) δ : 7.42 (t, 1H, *J* = 7.4 Hz), 7.26-7.16 (m, 1H), 7.12 (t, 1H, *J* = 7.4 Hz), 6.99 (t, 1H, *J* = 9.1 Hz), 4.89 (t, 1H, *J* = 6.5 Hz), 2.70 (bs, 1H), 1.83-1.66 (m, 2H), 0.91 (t, 3H, *J* = 7.3 Hz); ¹³C-NMR (75 MHz, CDCl₃) δ : 159.7 (*J* = 245.1 Hz), 131.4 (*J* = 13.3 Hz), 128.5 (*J* = 8.3 Hz), 127.3 (*J* = 4.6 Hz), 124.1 (*J* = 3.5 Hz), 115.0 (*J* = 22.0 Hz), 69.3, 30.8, 9.8.

(*S*)-1-(2-chlorophenyl)propan-1-ol 18m:²⁶ 163 mg, >95%; colorless oil; $[α]^{25}_{D} = -48.6$; *ee* = 91% (HPLC: Chiralpack IA, hexane/i-PrOH 99.5/0.5, 1 mL/min, 225 nm, minor 29.6 min and major 32.4 min). ¹H-NMR (300 MHz, CDCl₃) δ: 7.49 (dd, 2H, *J* = 7.6, 1.7 Hz), 7.32-7.20 (m, 2H), 7.16 (dd, 2H, *J* = 7.7, 1.7 Hz), 5.02 (dd, 1H, *J* = 7.5, 4.9 Hz), 2.86 (bs, 1H), 1.85-1.60 (m, 2H), 0.95 (t, 3H, *J* = 7.3 Hz); ¹³C-NMR (75 MHz, CDCl₃) δ: 141.9, 131.8, 129.1, 128.1, 127.1, 126.8, 71.6, 30.4, 9.9.

(*S*)-1-(3-bromophenyl)propan-1-ol 18n:²⁸ 205 mg, >95%; colorless oil; $[\alpha]^{25}_{D}$ = -26.2 (*c* 2.8, CHCl₃); *ee* = 88% (HPLC: Chiralpack IA, hexane/i-PrOH 98/2, 0.9 mL/min, 267 nm, minor 15.6 min and major 16.4 min); ¹H-NMR (300 MHz, CDCl₃) δ : 7.47-7.29 (m, 2H), 7.21-7.11 (m, 2H), 4.46 (t, 1H, *J* = 6.5 Hz), 2.90 (bs, 1H), 1.75-1.57 (m, 2H), 0.86 (t, 3H, *J* = 7.3 Hz); ¹³C-NMR (75 MHz, CDCl₃) δ : 146.7, 130.2, 129.7, 128.9, 124.5, 122.3, 74.9, 31.7, 9.8.

(*S*)-1-(4-bromophenyl)propan-1-ol 18o:²⁸ 191.4 mg, 89%; colorless oil; $[\alpha]^{25}_{D} = -35.5$ (*c* 3.8, CHCl₃); *ee* = 96.6% (HPLC: Chiralpack IC, hexane/i-PrOH 99/1, 1.5 mL/min, 220 nm, minor 7.4 min and major 8.6 min); ¹H-NMR (300 MHz, CDCl₃) δ : 7.44 (d, 2H, *J* = 8.4 Hz), 7.17 (d, 2H, *J* = 8.4 Hz), 4.51 (t, 1H, *J* = 6.5 Hz), 2.33 (bs, 1H), 1.81-1.57 (m, 2H), 0.87 (t, 3H, *J* = 7.4 Hz); ¹³C-NMR (75 MHz, CDCl₃) δ : 143.4, 131.2, 127.6, 120.9, 75.0, 31.7, 9.9.

3-(1-hydroxypropyl)benzonitrile 18p: absolute configuration not available, 155 mg, >95%; colorless oil; $[\alpha]^{25}_{D}$ = -38.4 (*c* 4.4,

CHCl₃); *ee* = 96% (HPLC: Chiralpack IA, hexane/i-PrOH.95/S_{totl} = mL/min, 220 nm, minor 13.06 min and Major 144928 MM),¹⁶H² NMR (300 MHz, CDCl₃) δ : 7.54-7.30 (m, 4H), 4.52 (t, 1H, *J* = 6.6 Hz), 2.41 (bs, 1H), 1.73-1.54 (m, 2H), 0.82 (t, 3H, *J* = 7.3 Hz); ¹³C-NMR (75 MHz, CDCl₃) δ : 146.0, 130.6, 130.4, 129.3, 128.8, 118.7, 111.6, 74.2, 31.7, 9.6.

(S)-4-(1-hydroxypropyl)benzonitrile 18q:²⁹ 150 mg, 93%; colorless oil; $[\alpha]^{25}_{D} = -37.7$ (*c* 2.8, CHCl₃); *ee* = 92% (HPLC: Chiralpack IA, hexane/i-PrOH 95/5, 0.8 mL/min, 220 nm, minor 17.3 min and major 18.8 min); ¹H-NMR (300 MHz, CDCl₃) δ : 7.58 (d, 2H, *J* = 8.2 Hz), 7.42 (d, 2H, *J* = 8.2 Hz), 4.63 (t, 1H, *J* = 6.4 Hz), 2.57 (bs, 1H), 1.79-1.66 (m, 2H), 0.89 (t, 3H, *J* = 7.4 Hz); ¹³C-NMR (75 MHz, CDCl₃) δ : 150.1, 131.8, 126.4, 118.6, 110.2, 74.4, 31.6, 9.5.

Conflicts of interest

There are no conflicts to declare.

Notes and references

§ The allyl group was chosen as it could eventually be converted through a Pt-catalyzed hydrosilylation into a trialcoxysilane, anchorable on magnetite nanoparticles.

§§ Using as Lewis acid Al_2O_3 (M. Noguchi, M. Yoshioka, S. Kakimoto, S. Kajigaeshi Bull. Chem. Soc. Jpn. 1987, 60, 3261-3267) Ti(Oi-Pr)₄ or ZnCl₂ the starting substrate was completely recovered even at high temperature and long reaction time.

§§§ Unfortunately, **13f** and **14** were chromatographically inseparable and the compounds' separation and identification was achieved by an acetylation of the hydroxyl group; a following hydrolysis allowed to obtain **13f** and **14**.

§§§§ All the substrates were prepared starting from the corresponding allylic alcohols. For the substrate with R=cyclohexyl the appropriate alcohol is not commercially available and it was synthesized from the cyclohexanecarboxaldehyde, by a Horner-Emmons reaction followed by a reduction of the ester using DIBAL (A. G. M. Barrett, W. W. Doubleday, G. J. Tustin, *Tetrahedron* **1996**, 52, *48*, 15325-15338).

- 1 W.S. Knowles, Angew. Chem. Int. Ed. 2002, 41, 1998-2007
- 2 R. Noyori, Angew Chem Int Ed. 2002, 41, 2008-2022.
 - K.B. Sharpless, Angew. Chem. Int. Ed. 2002, 41, 2024-2032
- 4 a) D. Ager, I. Prakash, D. R. Schaad, Chem Rev. 1996, 96, 835-876. b) J. Vicario, D. Badia, L. Carrillo, E. Reyes, J. Etxebarria, Current Organic Chemistry 2005, 9, 219-235
- 5 M. Kitamura, S. Suga, K. Kawai, R. Noyori, J. Am. Chem. Soc. 1986, 108, 6071-6072.
- 6 K. Soai, S. Yokoyama, T. Hayasaka, J. Org. Chem. 1991, 56, 4264-4268
- 7 A. Vidal-Ferran, A. Moyano, M. A. Pericàs, A. Riera J. Org. Chem. 1997, 62, 4970-4982
- 8 W. A. Nugent Org. Lett. 2002, 4, 2133-2136
- 9 G. Righi and S. Ciambrone, *Tetrahedron Lett.* 2004, **45**, 2103-2106.
- 10 G. Righi, P. Bovicelli and I. Tirotta, *Tetrahedron Lett.* 2013, 54, 6439-6442.

This journal is $\ensuremath{\mathbb{C}}$ The Royal Society of Chemistry 20xx

3

View Article Online DOI: 10.1039/C8OB00165K

- 11 Review: L. M. Rossi, N. J. S. Costa, F. P. Silva, R. Wojcieszak, *Green Chem.* 2014, **16**, 2906-2933.
- 12 R. De Palma, S. Peeters, M. J. Van Bael, H. Van den Rul, K. Bonroy, W. Laureyn, J. Mullens, G. Borghs, G. Maes, *Chem. Mater.* 2007, **19**, 1821-1831.
- 13 Review: S. Shylesh, V. Schuneman and W. R Thiel, *Angew. Chem., Int. Ed.* 2010, **49**, 3428-3459.
- 14 R. Noyori, M. Kitamura, Angew. Chem., Int. Ed. Engl. 1991, **30**, 49-69.
- 15 G. Righi, A. Mantineo, L. Suber, A. Mari, *Synlett* 2012, **23**, 1947-1949.
- 16 M.Yamakawa, R. Noyori, J. Am. Chem. Soc. 1995, 117, 6327-6335.
- 17 M. Yamakawa, R. Noyori, Organometallics 1999, 18, 128-133.
- Y. Gao, R. M. Hanson, J. M. Klunder, S. Y. Ko, H. Masamune, K. B. Sharpless, J. Am. Chem. Soc. 1987, 109, 5765-5780.
- 19 R. Nishizawa, T. Nishiyama, K. Hisaichi, C. Minamoto, M. Murota, Y. Takaoka, H. Nakai, H. Tada, K. Sagawa, S. Shibayama, D. Fukushima, K. Maeda, H. Mitsuya, *Bioorg. Med. Chem.* 2011, **19**, 4028–4042.
- 20 G Righi, A Chionne, C. Bonini, *Eur. J. Org. Chem.* 2000, 3127-3131.
- 21 M. Asami, S. Inoue, Bull. Chem. Soc. Jpn. 1997, 70, 1687–1690.
- 22 C. Andres, R. Infante, J. Nieto, *Tetrahedron: Asymmetry* 2010, **21**, 2230–2237.
- 23 M. A. Aga, B. Kumar, A. Rouf, B. A. Shah, S. C. Taneja, Tetrahedron Lett. 2014, 55, 2639-2641
- 24 Z.-L. Wu, H.-L. Wu, P.-Y. Wu, B.-J. Uang, Tetrahedron: Asymmetry 2009, **20**, 1556–1560.
- 25 W.-X. Zhao, N. Liu, G.-W. Li, D.-L. Chen, A.-A. Zhang, M.-C. Wang, L. Liu, *Green Chemistry* 2015, **17**, 2924-2930.
- 26 X.-F. Yang, T. Hirose, G.-Y. Zhang, *Tetrahedron: Asymmetry* 2008, **19**, 1670–1675.
- 27 A. Kokura, S. Tanaka, T. Ikeno, T. Yamada, *Organic Letters* 2006, **8**, 3025-3027.
- 28 K. R. Prasad, O. Revu, Tetrahedron 2013, 69, 8422-8428.
- 29 Y.-S. Shih, R. Boobalan, C. Chen, G.-H. Lee, *Tetrahedron Asymmetry* 2014, **25**, 327-333